Completion of Phosphagenics’ transdermal insulin (TPM-02/Insulin) clinical trial confirming the successful delivery of insulin across skin in humans

Phosphagenics Limited (“Phosphagenics”) (ASX: POH) (AIM: PSG) announced today that it has received the final report of its Phase I transdermal insulin clinical trial.

The final report confirms the conclusions of the interim results announced in August, that Phosphagenics had successfully delivered insulin through the skin in humans by means of its patented TPM-02/Insulin delivery system. The key findings as previously announced, were that TPM-02/Insulin, when applied as a gel, delivered insulin through the skin and into the bloodstream and exerted its physiological effect of lowering blood glucose levels. Importantly, TPM-02/Insulin did not produce any adverse reactions.

The new finding contained in the final study report was the detection of exogenous insulin (externally-applied insulin) in the circulation of volunteers who received TPM-02/Insulin. This additional data, in conjunction with the blood glucose, endogenous insulin and c-peptide results of the trial announced in August, demonstrate the ability of TPM-02/Insulin to deliver insulin into the blood stream and to produce significant effects.

ENDS….

APPENDIX AND NOTES TO EDITORS

About Phosphagenics’ Transdermal Carrier Technology

Phosphagenics’ patented transdermal carrier technology (TPM) utilises natural dermal transport mechanisms to rapidly transport small and large molecules across the skin without disrupting or damaging its surface.

The Company believes that the key advantages of this delivery system includes the fact that it possesses anti-inflammatory and anti-erythema properties, thus minimising skin irritation, and has the ability to provide a sustained systemic delivery of a wide range of drugs ­– ranging from relatively small molecules (e.g. morphine, fentanyl, oxycodone, atropine, estradiol, testosterone) to large molecules (e.g. insulin and PTH) – from a single application. Additionally, the TPM delivery technology can be cost-effectively manufactured in a wide range of presentations (e.g. gel, paste, liquid and powder) adding value to existing pharmaceuticals.

About Phosphagenics Limited
Phosphagenics is a Melbourne-based, globally driven biotechnology company focused on the discovery of new and cost effective ways to enhance the bioavailability, activity, safety and delivery of proven pharmaceutical and nutraceutical products.

Phosphagenics’ core technology is built around the science and application of phosphorylation, a process where the addition of a phosphate group has been found to enhance the bioavailability, activity and safety of existing pharmaceuticals and nutraceuticals, as well as to assist in the production of drug delivery platforms.

Phosphagenics’ shares are listed on the Australian Stock Exchange (POH) and the London Stock Exchange's Alternative Investment Market (PSG). An ADR – Level 1 program has been established in the US with the Bank of New York (PPGNY) for US investors to trade in Phosphagenics’ stock on the ‘over-the-counter’ market.  

For more information, please visit Phosphagenics’ web site at 

www.phosphagenics.com

Contact details:

Dr Esra Ogru

Phosphagenics Ltd

Executive Director Research & Development

+61 3 9605 5900 or +61 (0) 402 080 846 

Mr Harry Rosen

Phosphagenics Ltd

Managing Director

+61 3 9605 5900 or +61 (0)421 322 757